



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/074,687

02/11/2002

Feng-Jing Chen

6200-0004.20

9747

20551

7590

08/24/2006

THORPE NORTH & WESTERN, LLP.
8180 SOUTH 700 EAST, SUITE 200
SANDY, UT 84070

EXAMINER

CHANNAVAJJALA, LAKSHMI SARADA

ART UNIT

PAPER NUMBER

1615

DATE MAILED: 08/24/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 10/074,687	Applicant(s) CHEN ET AL.	
	Examiner Lakshmi S. Channavajjala	Art Unit 1615	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 05 June 2006.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-145 is/are pending in the application.
- 4a) Of the above claim(s) 3,4,18-23,38,67-71,88-93,108 and 135-145 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1, 2, 5-17, 24-37, 39-66, 72-87, 94-107 and 109-133 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Receipt of response dated 6-5-06 is acknowledged.

Claims 1-145 are pending in the instant application.

Claims 1, 2, 5-17, 24-37, 39-66, 72-87, 94-107 and 109-133 have been examined.

Claims 3, 4, 18-23, 38, 67-71, 88-93, 108 and 135-145 are withdrawn from consideration as being non-elected.

In response to applicants' argument, the rejection of the previous action has been withdrawn and the following rejection has been applied:

Claim Rejections - 35 USC § 102

Claims 1, 5-10, 24-29, 36, 37, 39-47, 59, 60, 72-80, 94-99, 106-107, 109-114, 126-127 are rejected under 35 U.S.C. 102(b) as being anticipated by US 4,897,269 to Mezei et al (Mezei).

Mezei discloses a pharmaceutical product in which a biologically active agent is present in a multiphase system i.e., A) captured in a multilamellar lipid vesicle, B) dissolved in the solvent component and C) in a solid crystalline or amorphous state (col. 4, lines 5-20), the product being dispersed in a hydrocolloid gel. Thus, the components B and C of Mezei read on the instant second and first fractions of the active agents, respectively. Examples listed in col. 7-16 (examples 1-11), include solvents such as ethanol, polyethylene glycol, which meet the requirement of the claimed solubilizers (claims 1, 43-46 and 113). With respect to the claimed percentages of the active agent (claims 5-7 and 75-77), the amount of the active agents in the examples above falls

Art Unit: 1615

within the claimed percentages. Instant claims do not exclude liposomal formulations of Mezei. The solid particles of Mezei read on the limitations of claims 8, 9, 29, 78, 79 and 99 and the product meet the limitations of claims 1, 72 and 74.

For claims 10 and 80, Mezei discloses that the solid state of the active agent is encapsulated within the lipid vesicles. Instant claims recite that the solid particle is with a capsule but fails to state what the nature of the capsule.

For claims 24-28 and 94-98, Mezei teaches excipients such as methylcellulose (examples), which is recited in claims 28 and 98.

The composition of Mezei does not contain any water indispersible waxes and hence meet the limitations of claims 36, 37, 106 and 107. Further, the composition of Mezei does not contain water (see examples 1-9) and hence meet the claims 39, 40, 109 and 110.

With respect to the active agents of claims 47 and 114, Mezei teaches anti-fungal agent, econazole (example 6).

For claims 59, 60, 126 and 127, the composition of Mezei comprises a pharmaceutically active agent, which inherently possesses a release profile and further due to the presence of the active agent in a solid as well as a solution form, the release of the active agent in different states occurs at different rates.

Thus, Mezei anticipates the instant claims.

Claim Rejections - 35 USC § 103

Claims 2, 11-17, 48, 49, 51-58, 61-66, 81-87, 115-116, 118-125, and 128-133 are rejected under 35 U.S.C. 103(a) as being unpatentable over US 4,897,269 to Mezei et al (Mezei).

Mezei does not teach the specific drugs (claims 49, 51-53, 55, 57, 115-116, 118-120, 122, 124), release properties (61-66 & 128-133), process of preparing solid particles (claims 11-17 & 81-87), claimed in the instant application. However, Mezei teaches that the different forms of active agent (solid and solution) have different rates of absorption, distribution and metabolism and therefore, absent evidence to the contrary, one of the forms of the active agent of Mezei is released earlier than the other (immediate and delayed) (col. 5, L 10-20 & col. 7, L 7-13). With respect to preparing the solid particles, Mezei suggests particles of active in the same size range as claimed (col. 12, L 25-30). Accordingly, in the absence of any unexpected advantage with the claimed method of preparing solid particles, one of an ordinary skill in the art at the time of the instant invention would have readily obtained active agent particles in the claimed range because Mezei suggests that the preparation of the multicomponent system with solid particles of claimed sizes. Mezei also suggests incorporating a number of hydrophobic drugs, (col. 6, lines 4-27), more particularly estradiol, progesterone etc (col. 9, last 4 lines) and accordingly choosing an appropriate drug in the preparation of the product of Mezei with an expectation to achieve a release preparation with different release, absorption or metabolic rates due to different forms of active agent (solid and solution) would have been obvious for of an ordinary skill in the art at the time of the

Art Unit: 1615

instant invention was made. Mezei fails to teach the claimed surfactants in the composition.

Allowable Subject Matter

Claims 30-35, 50, 100-105 and 117 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

The prior art of record teaches pharmaceutical composition with an active agent in the form of solid particles as well as a soluble fraction in the same product. However, the prior art does not teach or suggest the addition of a stabilizing agent to the solid particulate fraction of the active agent. While the art of record suggests different classes of hydrophobic drugs in general, to be incorporated in the dosage form, the prior art of record does not teach the specific lipid-regulating agent fenofibrate.

Response to Arguments


Applicant's arguments filed 6-5-06 have been fully considered but they are not persuasive. Applicants' arguments with respect to the teachings of Lacy et al or Lacy et al in view of Mezei et al are moot because the rejections have been withdrawn. Applicants argued that Mezei teaches a formulation comprising lipid vesicles and that the reference is primarily focused on topical formulations. However, instant claims do not exclude the limitations argued and the claims are not limited to any specific dosage form.

Art Unit: 1615

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Lakshmi S. Channavajjala whose telephone number is 571-272-0591. The examiner can normally be reached on 9.00 AM -6.30 PM

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward can be reached on 571-272-8373. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



Lakshmi S Channavajjala

Examiner

Art Unit 1615

August 20, 2006